Functional Distinctions of Endometrial Cancer-Associated Mutations in the Fibroblast Growth Factor Receptor 2 Gene
Cells · 2023
DOI: 10.3390/cells12182227 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cells, 2023. Verfasst von Garima Dixit und 4 weiteren Autor:innen. Beteiligte Einrichtung: Inflammation Program and Division of Infectious Diseases, Department of Internal Medicine, Roy J. and Lucille A. Carver College of Medicine, Universi…. Hauptthemen laut MEDLINE: Receptor, Fibroblast Growth Factor, Type 2, Endometrial Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, American Cancer Society, American Heart Association Career Development Award.
Abstract (Originalsprache)
Functional analysis of somatic mutations in tumorigenesis facilitates the development and optimization of personalized therapy for cancer patients. The fibroblast growth factor receptor 2 (FGFR2) gene is frequently mutated in endometrial cancer (EC), but the functional implications of FGFR2 mutations in cancer development remain largely unexplored. In this study, we introduced a reliable and readily deployable screening method to investigate the effects of FGFR2 mutations. We demonstrated that distinct mutations in FGFR2 can lead to differential downstream consequences, specifically affecting a disintegrin- and metalloprotease 17 (ADAM17)-dependent shedding of the epidermal growth factor receptor (EGFR) ligand heparin-binding EGF-like growth factor (HB-EGF) and phosphorylation of mitogen-activated protein kinases (MAPKs). Furthermore, we showed that the distribution of mutations within the FGFR2 gene can influence their oncogenic effects. Together, these findings provide important insights into the complex nature of FGFR2 mutations and their potential implications for EC. By unraveling the distinct effects of different mutations, our study contributes to the identification of personalized treatment strategies for patients with FGFR2-mutated cancers. This knowledge has the potential to guide the development of targeted therapies that specifically address the underlying molecular alterations associated with FGFR2 mutations, ultimately improving patient outcomes in EC and potentially other cancer types characterized by FGFR2 mutations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Inflammation Program and Division of Infectious Diseases, Department of Internal Medicine, Roy J. and Lucille A. Carver College of Medicine, University of Iowa, Iowa City, IA 52242, USA.
- Fraternal Order of Eagles Diabetes Research Center and Division of Endocrinology and Metabolism, Department of Internal Medicine, Roy J. and Lucille A. Carver College of Medicine, University of Iowa, Iowa City, IA 52242…
- Immunology Graduate Program, Roy J. and Lucille A. Carver College of Medicine, University of Iowa, Iowa City, IA 52242, USA.
- Holden Comprehensive Cancer Center, Roy J. and Lucille A. Carver College of Medicine, University of Iowa, Iowa City, IA 52242, USA.
ORCID-Profile: Garima Dixit, Gourav Bhardwaj
Förderung
- NCI NIH HHS
- American Cancer Society
- American Heart Association Career Development Award
- Carver Trust Collaborative Pilot
- Carver College of Medicine University of Iowa Research Start-Up
Zitieren
APA
Dixit, G., Pappas, B. A., Bhardwaj, G., Schanz, W., & Maretzky, T. (2023). Functional Distinctions of Endometrial Cancer-Associated Mutations in the Fibroblast Growth Factor Receptor 2 Gene. Cells. https://doi.org/10.3390/cells12182227
Vancouver
Dixit G, Pappas BA, Bhardwaj G, Schanz W, Maretzky T. Functional Distinctions of Endometrial Cancer-Associated Mutations in the Fibroblast Growth Factor Receptor 2 Gene. Cells. 2023. doi:10.3390/cells12182227
BibTeX
@article{Dixit2023,
author = {Dixit, Garima and Pappas, Benjamin A and Bhardwaj, Gourav and Schanz, Willow and Maretzky, Thorsten},
title = {Functional Distinctions of Endometrial Cancer-Associated Mutations in the Fibroblast Growth Factor Receptor 2 Gene},
journal = {Cells},
year = {2023},
doi = {10.3390/cells12182227}
}
EUVIMED